Significance of Examined Lymph Node Number in Accurate Staging and Long-term Survival in Resected Stage I-II Pancreatic Cancer-More is Better? A Large International Population-based Cohort Study
- PMID: 31425290
- DOI: 10.1097/SLA.0000000000003558
Significance of Examined Lymph Node Number in Accurate Staging and Long-term Survival in Resected Stage I-II Pancreatic Cancer-More is Better? A Large International Population-based Cohort Study
Abstract
Objective: This large international cohort study aimed to investigate the associations of examined lymph node (ELN) number with accurate staging and long-term survival in pancreatic adenocarcinoma (PaC) and to robustly determine the minimal and optimal ELN thresholds.
Summary background data: ELN number is an important quality metric in cancer care. The recommended minimal ELN number in PaC to accurately stage cancer varies greatly across guidelines, and the optimal number especially to adequately stratify patient survival has not yet been established.
Methods: Population-based data on patients with stage I to II PaC resected in 2003 to 2015 from the US Surveillance, Epidemiology, and End Results (SEER)-18 Program and Netherlands National Cancer Registry (NCR) were analyzed. Associations of ELN number with stage migration and survival were evaluated using multivariable-adjusted logistic and Cox regression models, respectively. The series of odds ratios (ORs) for negative-to-positive node stage migration and hazard ratios (HRs) for survival with more ELNs were fitted using a LOWESS smoother, and structural breakpoints were determined by Chow test.
Results: Overall 16,241 patients were analyzed. With increasing ELN number, both cohorts exhibited significant proportional increases from nodenegative to node-positive disease [ORSEER-18 = 1.05, 95% confidence interval (CI) = 1.04-1.05; ORNCR = 1.10, 95% CI = 1.08-1.12] and serial improvements in survival (HRSEER-18 = 0.98, 95% CI = 0.98-0.99; HRNCR = 0.98, 95% CI = 0.97-0.99) per additional ELN after controlling for confounders. Associations for stage migration and survival remained significant in most stratifications by patient, tumor, and treatment factors. Cut-point analyses suggested a minimal threshold ELN number of 11 and an optimal number of 19, which were validated both internally in the derivative US cohort and externally in the Dutch cohort with the ability to well discriminate different probabilities of both survival and stage migration.
Conclusions: In stage I to II PaC, more ELNs are associated with more precise nodal staging, which might largely explain the survival association. Our observational study does not suggest causality, and does not encourage more extended lymphadenectomy before further randomized evidence is obtained. Our results robustly conclude 11 ELNs as the minimal and suggest 19 ELNs as the optimal cut-points, for evaluating quality of lymph node examination and possibly for stratifying postoperative prognosis.
Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
The authors report no conflicts of interest.
Comment in
-
Comment on "Optimal Number of Examined Lymph Node May Dependent on Age in Patients With Pancreatic Adenocarcinoma".Ann Surg. 2021 Dec 1;274(6):e673-e674. doi: 10.1097/SLA.0000000000003811. Ann Surg. 2021. PMID: 32209900 No abstract available.
-
Response to the Comment on "Optimal Number of Examined Lymph Node May Depend on Age in Patients With Pancreatic Adenocarcinoma".Ann Surg. 2021 Dec 1;274(6):e674-e675. doi: 10.1097/SLA.0000000000004449. Ann Surg. 2021. PMID: 33086330 No abstract available.
-
Importance of an appropriate number of examined lymph nodes in patients with pancreatic cancer-the more the better?Hepatobiliary Surg Nutr. 2022 Aug;11(4):605-607. doi: 10.21037/hbsn-22-163. Hepatobiliary Surg Nutr. 2022. PMID: 36016730 Free PMC article. No abstract available.
-
The prognostic relevance of examined lymph nodes for accurate staging of resected pancreatic adenocarcinoma.Hepatobiliary Surg Nutr. 2022 Aug;11(4):632-635. doi: 10.21037/hbsn-2022-14. Hepatobiliary Surg Nutr. 2022. PMID: 36016747 Free PMC article. No abstract available.
References
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018; 68:7–30.
-
- Malvezzi M, Carioli G, Bertuccio P, et al. European cancer mortality predictions for the year 2018 with focus on colorectal cancer. Ann Oncol 2018; 29:1016–1022.
-
- Huang L, Jansen L, Balavarca Y, et al. Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. Gut 2019; 68:130–139.
-
- Khorana AA, Mangu PB, Berlin J, et al. Potentially curable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2017; 35:2324–2328.
-
- Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2017; 15:1028–1061.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical